With plenty of GLP-1 money to spend, Eli Lilly and Co. is buying Verve Therapeutics Inc. and its gene-editing program for about $1.3 billion. Two of Verve’s one-time treatments are in the clinic. Lead candidate VERVE-102, a gene-editing treatment targeting PCSK9, is in a phase Ib study to reduce cholesterol levels. Read More

Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa monoclonal antibody, garadacimab (CSL-312), to prevent hereditary angioedema attacks. Read More

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo proteins that fold in a particular way and bind to prespecified target proteins. The sister system, called Alphadesign, works by generating random strings of amino acids, using Alphafold to predict their structure, and then iteratively optimizing the design. Read More

Shares of Nextcure Inc. (NASDAQ:NXTC) dropped 26.27% on news of a potential $745 million partnership with Simcere Zaiming for Simcere’s cadherin-6 antibody-drug conjugate (ADC) candidate. Shares ended at 50 cents apiece June 16. Read More

The 17 members abruptly terminated June 9 from the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) are not going gently into the night. Instead, they’re raging against what could be the dying of the light. The 17 raised their collective voices in a June 16 JAMA opinion piece to decry what’s at stake with Health and Human Services Secretary Robert Kennedy’s efforts, in his words, to “reestablish public confidence in vaccine science” by cleansing ACIP of what he claimed were conflicts due to members’ financial ties to industry. Read More

For years, the biopharma industry has spent increasing amounts of money on R&D without improving success rates, leaving many executives searching for new, more predictable drug development paths. Read More

The revised trial protocol that means a delay in filing for U.S. approval of DYNE-101 to treat myotonic dystrophy type 1 (DM1) dented shares of Dyne Therapeutics Inc. (NASDAQ:DYN), which closed June 17 at $10.86, down $2.96, or 21%. Read More

Stay updated with BioWorld's latest index insights, featuring sector-specific charts that track the performance of companies in biopharma, drug development, cancer research, infectious diseases and neurological diseases. This page offers updates on index movement, as well as links to relevant stories about the biggest gainers and losers within each index. Explore the BioWorld index insights page for in-depth, real-time data and performance analysis. Read More

New hires and promotions in the biopharma industry, including: BMS, Hepion, Pharmadrug, Solu, Syncromune. Read More

Biopharmas raising money in public or private financings, including: Alzecure, Klotho. Read More

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abbvie, Abelzeta, ADC, Akeso, Amplia, Ascentage, Astrazeneca, Biocryst, BMS, Brainstorm, Clarametyx, D&D, Eolo, Genmab, Halia, Incyte, Intellia, Janssen-Cilag, Jasper, Johnson, Kalvista, Lantern, Pharvaris, Regeneron, Roche, Sanofi, Sarepta, Tonix, Windtree, X4. Read More

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Antares, Crescent, Endo, Fosun, Glycomimetics, Help, Incyte, Mallinckrodt, Nextcure, Pierre Fabre, Poltreg, Qiagen, Simcere, Teva. Read More

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Aquestive, Ark, Averoa, Celltrion, Centessa, Circle, Kalvista, MBX, Milestone, Ocugen, Solascure. Read More